Hikma Pharmaceuticals PLC (fra:H5P) Share Price

Company Profile

Business description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Contact
1 New Burlington Place
LondonW1S 2HR
GBR
T: +44 2073992760
E: [email protected]
https://www.hikma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
9,500

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.50	34.00	-0.37%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,548.27	109.76	0.42%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,652.08	749.81	1.67%
NZX 50 Index	13,222.12	12.77	-0.10%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,800.00	48.50	-0.55%
SSE Composite Index	3,822.12	9.54	-0.25%